Damaged vascular endothelium and subendothelial matrix

The damaged vascular endothelium and subendothelial matrix represent a pathological state where the protective endothelial cell layer is disrupted, exposing the underlying basement membrane and interstitial proteins to the blood [StatPearls, 2023]. This exposure reveals highly pro-thrombotic molecules such as Type I and III collagen, von Willebrand factor (vWF), and tissue factor, which initiate platelet adhesion, activation, and the coagulation cascade [Nature Reviews Cardiology, 2021]. In the context of drug development, this environment is increasingly utilized as a site-specific target for smart delivery systems, including nanoparticles and antibody-drug conjugates designed to home specifically to injured vessels [Advanced Drug Delivery Reviews, 2011]. By targeting the unique molecular signatures of the exposed matrix, these therapies aim to concentrate anti-inflammatory or anti-thrombotic agents at the site of disease, such as an atherosclerotic plaque or a site of vascular trauma, thereby enhancing efficacy and reducing systemic toxicity [Journal of Controlled Release, 2018]. However, because this target is a complex multi-protein environment rather than a single molecular entity, achieving high specificity without interfering with normal hemostasis remains a significant therapeutic challenge [Pharmacological Reviews, 2017].

Other names

Injured vessel wallExposed subendothelial matrixDenuded endotheliumVascular injury site

Selective binding to exposed extracellular matrix components (e.g., Collagen, von Willebrand Factor) or injury-induced adhesion molecules (e.g., P-selectin) to localize therapeutic action or inhibit platelet-vessel wall interactions [Nature Reviews Cardiology, 2021].